Navigation Links
Ikaria Introduces Dr. Michael Cooreman as Vice President of Translational Medicine
Date:6/24/2008

Translational Medicine Department Strengthens Research & Development Team

CLINTON, N.J., June 24 /PRNewswire/ -- Ikaria Holdings, Inc., a fully integrated critical care biotherapeutics company, announced that Michael Cooreman, M.D., has been introduced as Vice President of Translational Medicine, reporting to Ralf Rosskamp, M.D., Executive Vice President for Research and Development of Ikaria.

As Vice President of Translational Medicine, Dr. Cooreman is responsible for leading the Company's Translational Medicine Department. Translational Medicine seeks to define as early as possible the indications for which a new compound will most likely show therapeutic benefit, based on the known interaction of the compound in disease pathways, in addition to confirmation of safety and efficacy of that compound in animal studies. Once likely indications are determined, a clinical proof-of-concept study is initiated with the goal of demonstrating clinical safety, pharmacokinetic properties and therapeutic efficacy study in a particular disease. The results are used to make a data-based decision on whether or not to initiate a Phase 3 trial.

Dr. Rosskamp commented, "In this recently created position, Michael will help us translate pre-clinical research findings into meaningful, early clinical trials. Translational Medicine is often defined as 'bench-to-bedside' research and represents a paradigm shift of developing new drugs and devices. Rather than progressing a new drug or device from preclinical research through traditional Phase 1 to 3 development, we will now focus on a much earlier patient-oriented research. This will help Ikaria to accelerate our decision-making process on promising compounds and indications, which we believe will increase our success rate once we enter the costly late stage development phase."

Daniel Tasse, President & CEO of Ikaria, remarked, "Translational Medicine incorporates the use of tools such as biomarkers to bette
'/>"/>

SOURCE Ikaria Holdings, Inc.
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3

Related biology technology :

1. New Study Shows Promise for Hydrogen Sulfide in Reducing Heart-Attack Damage, Ikaria Announces
2. Ikaria Founding Scientist Named 2007 MacArthur Fellow
3. Ikaria to Present at 26th Annual JPMorgan Healthcare Conference
4. Ikaria Appoints Daniel Tasse as President and Chief Executive Officer
5. Lota Zoth Elected to Ikaria Board and Named Audit Committee Chair
6. SAFC Expands Hi-Potency API Manufacturing and Introduces Solid-Form Testing at Its Madison Facility
7. Caliper Life Sciences Introduces High Throughput RNA Assay to Improve Workflow in Gene Expression Studies
8. Small Bone Innovations Introduces the Artelon(R) STT Spacer to Increase Treatment Options for Thumb Arthritis
9. Small Bone Innovations Introduces New Distal Radius Plating System to Repair Complex Fractures
10. Advanced Instruments Introduces Worlds Fastest High Throughput Freezing Point Osmometer
11. Harmonex Introduces CliniCom(TM), a Breakthrough in Psychiatric Intake and Assessment Technology
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:8/26/2015)... SAN FRANCISCO , Aug. 26, 2015 /PRNewswire/ ... today that it has received a $1.5M Phase ... Health (NIH) to further develop its therapeutic agent ... unmet clinical need in end stage renal disease ... by the National Institute of Diabetes and Digestive ...
(Date:8/26/2015)... CORAL SPRINGS, Florida , August 26, 2015 ... one of the biggest factors fueling the optimism ... FDA approvals, M&A,s, collaborations and life sciences advancements.  ... and developments are Pressure BioSciences, Inc. (OTCQB: PBIO), ... Inc. (NASDAQ: SRPT ), Raptor Pharmaceutical Corp. ...
(Date:8/25/2015)... ... August 25, 2015 , ... Vets Plus, Inc. recently ... The company has added a AS16 Sharples centrifuge to harvest products after fermentation. ... or fungal fermentation process development. , The new centrifuge greatly expands production ...
(Date:8/25/2015)... Doximity, the leading medical network for ... its second annual Residency Navigator , an ... of doctors research and compare residency training programs ... senior medical students used Doximity to research the ... The new Residency Navigator brings an unprecedented level ...
Breaking Biology Technology:Symic Biomedical Awarded $1.5MM NIH Phase II SBIR Grant to Develop its Proteoglycan Mimetic Therapeutics to Reduce Vascular Access Failures in ESRD 2Symic Biomedical Awarded $1.5MM NIH Phase II SBIR Grant to Develop its Proteoglycan Mimetic Therapeutics to Reduce Vascular Access Failures in ESRD 3New Collaborations & Mergers For Research of Molecular Biomarkers in Human Diseases & Clinical Trials for Cancer Therapies Fueling Growth in Multi-Billion Dollar Life Sciences Market 2New Collaborations & Mergers For Research of Molecular Biomarkers in Human Diseases & Clinical Trials for Cancer Therapies Fueling Growth in Multi-Billion Dollar Life Sciences Market 3New Collaborations & Mergers For Research of Molecular Biomarkers in Human Diseases & Clinical Trials for Cancer Therapies Fueling Growth in Multi-Billion Dollar Life Sciences Market 4New Collaborations & Mergers For Research of Molecular Biomarkers in Human Diseases & Clinical Trials for Cancer Therapies Fueling Growth in Multi-Billion Dollar Life Sciences Market 5New Collaborations & Mergers For Research of Molecular Biomarkers in Human Diseases & Clinical Trials for Cancer Therapies Fueling Growth in Multi-Billion Dollar Life Sciences Market 6New Collaborations & Mergers For Research of Molecular Biomarkers in Human Diseases & Clinical Trials for Cancer Therapies Fueling Growth in Multi-Billion Dollar Life Sciences Market 7New centrifuge and fermentor expand product development capacity at Vets Plus 2Doximity Releases 2015-2016 Residency Navigator 2Doximity Releases 2015-2016 Residency Navigator 3
... shares of Common Stock in Exchange, for Senior Subordinated and ... ... interest, SEATTLE, Feb. 13 Cell Therapeutics, Inc.,("CTI" or the ... in aggregate principal of its outstanding 5.75%,Convertible Senior Subordinated Notes due 2008 ...
... (Nasdaq:,CEPH) issued the following statement in response to ... Commission (FTC) in U.S. District Court for the,District ... entered,into by the company in late 2005 and ... infringement litigation and seeking to,permanently enjoin the Company ...
... Board Authority to Implement Reverse Stock Split and ... Shares and Authorized Shares, NEW HAVEN, Conn., Feb. 13 ... Special Meeting of,Stockholders was held at the Omni Hotel in ... meeting, shareholders voted to approve amendments to the,Company,s Restated Certificate ...
Cached Biology Technology:Cell Therapeutics, Inc. (CTI) Announces Cancellation of Approximately $9.1 Million of Existing Notes due 2008 2Cephalon Statement on Federal Trade Commission Action Regarding PROVIGIL Patent Settlements 2Cephalon Statement on Federal Trade Commission Action Regarding PROVIGIL Patent Settlements 3Vion Pharmaceuticals Holds Special Meeting of Stockholders 2Vion Pharmaceuticals Holds Special Meeting of Stockholders 3
(Date:7/31/2015)... SHENZHEN , Kina, 31. juli 2015 ... ) bliver afholdt af BGI fra den 22. - 25. ... Konferencen fejrer sin 10-års fødselsdag i år. ... verdens mest indflydelsesrige årlige møder på ,omik,-feltet, og er ... forsamlinger. ICG-10 fokuserer på nylige gennembrud ...
(Date:7/31/2015)... SHENZHEN , Chine, 31 juillet 2015 /PRNewswire/ ... (ICG-10, www.icg-10.org ) sera organisée par le ... Shenzhen en Chine. ... année. Depuis son inauguration en 2006, l,ICG est ... influentes dans le domaine des « omiques » et c,est ...
(Date:7/31/2015)... OXFORD, Conn. , Jul. 31, 2015 NXT-ID, ... a biometric authentication company focused on the growing mobile ... announces that it has filed provisional patent 62/198989 for ... This invention highlights a method to advance crypto-currencies ... technology by introducing a common, uniform way to manage ...
Breaking Biology News(10 mins):Den 10. internationale konference om Genomics (ICG-10) åbner i oktober 2La 10e International Conference on Genomics (ICG-10) doit s'ouvrir en octobre 2La 10e International Conference on Genomics (ICG-10) doit s'ouvrir en octobre 3NXT-ID Patents Electronic Crypto-Currency Management Technology 2NXT-ID Patents Electronic Crypto-Currency Management Technology 3NXT-ID Patents Electronic Crypto-Currency Management Technology 4
... study of 60 beaches in Southern California suggests that ... highest levels when tides are ebbing during the new ... managers better assess the potential risk of swimming. , ... the American Chemical Society's journal Environmental Science & Technology. ...
... a healthy human gene to prevent blindness in mice ... strikes boys. , Writing in the August issue of ... how they successfully used gene therapy in mice to ... from mothers, who retain their sight, to their sons. ...
... a new laser therapy that destroys cancer cells but ... described in a study published in the Aug. 1 ... of Sciences (PNAS). , "One of the longstanding problems ... normal body tissue," says Hongjie Dai, an associate professor ...
Cached Biology News:Beach pollution is worst during new and full moon 2Gene therapy works in mice to prevent blindness that strikes boys 2Gene therapy works in mice to prevent blindness that strikes boys 3Scientists develop nanotech-laser treatment that kills cancer cells without harming healthy tissue 2Scientists develop nanotech-laser treatment that kills cancer cells without harming healthy tissue 3Scientists develop nanotech-laser treatment that kills cancer cells without harming healthy tissue 4
...
Mouse monoclonal [M2II-12] to MRP2 ( Abpromise for all tested applications). entrezGeneID: 1244 SwissProtID: Q92887...
Mouse monoclonal antibody to ANAPC2 - anaphase promoting complex subunit 2...
... MAX POWER 500V Programmable Power Supply ... which can handle virtually any application ... current blotting. It is unique in ... The MAX POWER Programmable Power Supply ...
Biology Products: